NASDAQ:BOLT Bolt Biotherapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.93 +0.07 (+3.76%) (As of 06/29/2022 11:58 AM ET) Add Compare Share Today's Range$1.81▼$1.9350-Day Range$1.41▼$2.1752-Week Range$1.39▼$19.29Volume3,492 shsAverage Volume273,116 shsMarket Capitalization$72.32 millionP/E RatioN/ADividend YieldN/APrice Target$24.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BOLT Stock Forecast (MarketRank)Overall MarketRank™2.16 out of 5 starsMedical Sector413th out of 1,433 stocksPharmaceutical Preparations Industry176th out of 685 stocksAnalyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 - 3.4 Analyst's Opinion Consensus RatingBolt Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.00, Bolt Biotherapeutics has a forecasted upside of 1,183.4% from its current price of $1.87.Amount of Analyst CoverageBolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.5 Community Rank Outperform VotesBolt Biotherapeutics has received 75 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBolt Biotherapeutics has received 34 “underperform” votes. (Add your “underperform” vote.)Community SentimentBolt Biotherapeutics has received 68.81% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Bolt Biotherapeutics and other stocks. Vote “Outperform” if you believe BOLT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BOLT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBolt Biotherapeutics does not currently pay a dividend.Dividend GrowthBolt Biotherapeutics does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions89.78% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($2.87) to ($2.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bolt Biotherapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bolt Biotherapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBolt Biotherapeutics has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bolt Biotherapeutics (NASDAQ:BOLT)Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.Read More BOLT Stock News HeadlinesJune 4, 2022 | americanbankingnews.comBolt Biotherapeutics (NASDAQ:BOLT) vs. Nektar Therapeutics (NASDAQ:NKTR) Critical ComparisonMay 26, 2022 | finance.yahoo.comThe past year for Bolt Biotherapeutics (NASDAQ:BOLT) investors has not been profitableMarch 30, 2022 | finance.yahoo.comBolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business HighlightsMarch 30, 2022 | seekingalpha.comBolt Biotherapeutics GAAP EPS of -$0.73 misses by $0.04, revenue of $0.51MMarch 8, 2022 | finance.yahoo.comBolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022February 10, 2022 | finance.yahoo.comBolt Biotherapeutics, Inc. (BOLT)February 2, 2022 | finance.yahoo.comBolt Biotherapeutics to Participate in Upcoming February ConferencesJanuary 6, 2022 | finance.yahoo.comBolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid TumorsDecember 11, 2021 | marketwatch.comBolt Biotherapeutics Shares Rise 12% After CFO Buys 5,000 SharesDecember 6, 2021 | finance.yahoo.comBolt Biotherapeutics Stock Halves on Mediocre Trial DataDecember 6, 2021 | finance.yahoo.comWhy Bolt Biotherapeutics Stock Crashed TodayDecember 6, 2021 | marketwatch.comBolt Biotherapeutics Interim Data Shows BDC-1001 Cancer Treatment Well-ToleratedDecember 6, 2021 | finance.yahoo.comBolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BOLT CUSIP09769810 CIK354655 Webwww.boltbio.com Phone650-665-9295FaxN/AEmployees91Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today6/29/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$24.00 High Stock Price Forecast$45.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+1,143.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98.59 million Net MarginsN/A Pretax Margin-4,718.52% Return on Equity-37.29% Return on Assets-30.78% Debt Debt-to-Equity Ratio0.09 Current Ratio10.16 Quick Ratio10.16 Sales & Book Value Annual Sales$1.26 million Price / Sales57.40 Cash FlowN/A Price / Cash FlowN/A Book Value$6.71 per share Price / Book0.29Miscellaneous Outstanding Shares37,472,000Free FloatN/AMarket Cap$72.32 million OptionableNot Optionable Beta2.01 Bolt Biotherapeutics Frequently Asked Questions Should I buy or sell Bolt Biotherapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Bolt Biotherapeutics stock. View analyst ratings for Bolt Biotherapeutics or view top-rated stocks. What is Bolt Biotherapeutics' stock price forecast for 2022? 4 Wall Street research analysts have issued 12 month target prices for Bolt Biotherapeutics' stock. Their BOLT stock forecasts range from $5.00 to $45.00. On average, they expect Bolt Biotherapeutics' share price to reach $24.00 in the next year. This suggests a possible upside of 1,143.5% from the stock's current price. View analysts' price targets for Bolt Biotherapeutics or view top-rated stocks among Wall Street analysts. How has Bolt Biotherapeutics' stock price performed in 2022? Bolt Biotherapeutics' stock was trading at $4.90 at the beginning of 2022. Since then, BOLT stock has decreased by 60.6% and is now trading at $1.93. View the best growth stocks for 2022 here. When is Bolt Biotherapeutics' next earnings date? Bolt Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Bolt Biotherapeutics. How were Bolt Biotherapeutics' earnings last quarter? Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) released its quarterly earnings results on Thursday, May, 12th. The company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.07. The business earned $0.81 million during the quarter, compared to analyst estimates of $1.38 million. View Bolt Biotherapeutics' earnings history. Who are Bolt Biotherapeutics' key executives? Bolt Biotherapeutics' management team includes the following people: Dr. Randall C. Schatzman Ph.D., CEO & Director (Age 67, Pay $830.67k)Dr. Edgar G. Engleman M.D., Founder & Independent Director (Age 76, Pay $31.58k)Mr. William P. Quinn, CFO & Sec. (Age 51, Pay $563.68k) (LinkedIn Profile)Mr. Grant Yonehiro C.F.A., M.B.A., Chief Bus. Officer (Age 58, Pay $519.98k)Dr. Edith A. Perez M.D., Chief Medical Officer (Age 65, Pay $627.32k)Dr. David Dornan Ph.D., Advisor (Age 44, Pay $580.08k)Ms. Karen L. Bergman, VP of Communications & Investor RelationsMr. Wesley Burwell, VP & Head of HR Who are some of Bolt Biotherapeutics' key competitors? Some companies that are related to Bolt Biotherapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of BOLT's competitors. What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Apellis Pharmaceuticals (APLS), Aquantia (AQ) and Aquinox Pharmaceuticals (AQXP). When did Bolt Biotherapeutics IPO? (BOLT) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities acted as the underwriters for the IPO. What is Bolt Biotherapeutics' stock symbol? Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT." Who are Bolt Biotherapeutics' major shareholders? Bolt Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.30%), Eventide Asset Management LLC (2.29%), Vanguard Group Inc. (2.26%), Renaissance Technologies LLC (0.77%), Northern Trust Corp (0.50%) and Echo Street Capital Management LLC (0.33%). Company insiders that own Bolt Biotherapeutics stock include Edgar Engleman, Randall C Schatzman, Vivo Capital Fund Viii, LP and William P Quinn. View institutional ownership trends for Bolt Biotherapeutics. Which major investors are selling Bolt Biotherapeutics stock? BOLT stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Goldman Sachs Group Inc., Vanguard Group Inc., Bank of America Corp DE, BlackRock Inc., Qube Research & Technologies Ltd, and Northern Trust Corp. View insider buying and selling activity for Bolt Biotherapeutics or view top insider-selling stocks. Which major investors are buying Bolt Biotherapeutics stock? BOLT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Echo Street Capital Management LLC, GSA Capital Partners LLP, PDT Partners LLC, and Bank of New York Mellon Corp. Company insiders that have bought Bolt Biotherapeutics stock in the last two years include Edgar Engleman, Randall C Schatzman, Vivo Capital Fund Viii, LP, and William P Quinn. View insider buying and selling activity for Bolt Biotherapeutics or or view top insider-buying stocks. How do I buy shares of Bolt Biotherapeutics? Shares of BOLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bolt Biotherapeutics' stock price today? One share of BOLT stock can currently be purchased for approximately $1.93. How much money does Bolt Biotherapeutics make? Bolt Biotherapeutics (NASDAQ:BOLT) has a market capitalization of $72.32 million and generates $1.26 million in revenue each year. The company earns $-98.59 million in net income (profit) each year or ($2.64) on an earnings per share basis. How many employees does Bolt Biotherapeutics have? Bolt Biotherapeutics employs 91 workers across the globe. How can I contact Bolt Biotherapeutics? Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for Bolt Biotherapeutics is www.boltbio.com. The company can be reached via phone at 650-665-9295 or via email at [email protected]. This page (NASDAQ:BOLT) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
